According to public information, Penghua Chinese Medicine ETF adopts passive index investment and closely tracks the CSI Chinese Medicine Index (93064 1). The index takes CSI Quan Zhi as the sample space, and selects the stocks of listed companies involved in the production and sales of traditional Chinese medicine as constituent stocks, so as to reflect the overall performance of listed companies with the concept of traditional Chinese medicine and provide diversified investment targets for the market. According to Wind's data, as of July 26, 2022, there were 50 constituent stocks of CSI Pharmaceutical Index, with a total market value exceeding 900 billion yuan. The weight of the top ten awkward stocks accounts for more than 55% of the total weight of the index. Since the benchmark date (65438+February 3, 20041), the cumulative increase of this index has reached 958.9438+0%. Compared with the increase of Shanghai and Shenzhen 300 and CSI 500 in the same period, the long-term excess return is considerable.
Looking ahead, Zhang Yuxiang, fund manager of Penghua TCM ETF, said that it is expected that the TCM sector will face a dilemma reversal. In recent years, the state has strongly supported the development of Chinese medicine, continuously introduced relevant policies, constantly standardized the approval standards for innovative Chinese medicine, and ushered in the incremental logic of supply-side reform; In the context of the valuation correction of the overall pharmaceutical sector, the Chinese medicine sector is expected to usher in a valuation reshaping.